<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119702</url>
  </required_header>
  <id_info>
    <org_study_id>HD052102 - PH300</org_study_id>
    <secondary_id>PH300</secondary_id>
    <nct_id>NCT02119702</nct_id>
  </id_info>
  <brief_title>Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)</brief_title>
  <acronym>AMP Up</acronym>
  <official_title>Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvard School of Public Health (HSPH)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NIH Office of AIDS Research (OAR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tulane University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvard School of Public Health (HSPH)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study designed to define the impact of HIV infection and&#xD;
      antiretroviral therapy (ART) on young adults with perinatal HIV infection as they transition&#xD;
      into adulthood. A group of perinatally HIV-exposed, -uninfected (PHEU) young adults from a&#xD;
      similar sociodemographic background and age distribution will be enrolled for comparison.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AMP Up aims to define the impact of HIV infection and antiretroviral therapy (ART) on young&#xD;
      adults with perinatal HIV infection as they transition into adulthood. A group of perinatally&#xD;
      HIV-exposed, -uninfected (PHEU) young adults from a similar sociodemographic background and&#xD;
      age distribution will be enrolled for comparison.&#xD;
&#xD;
      The primary objectives of this study are:&#xD;
&#xD;
        -  To identify infectious and non-infectious complications of HIV disease and toxicities&#xD;
           resulting from long-term ART, including disease progression, immune dysfunction, viral&#xD;
           resistance, end-organ disease, and mortality.&#xD;
&#xD;
        -  To define the impact of HIV infection and ART on the long-term clinical outcomes of&#xD;
           young adults, including:&#xD;
&#xD;
             -  Metabolic abnormalities and risk factors for cardiovascular disease, including&#xD;
                glucose and lipid metabolism, blood pressure, and body composition.&#xD;
&#xD;
             -  Sexually transmitted infections (Chlamydia trachomatis, Neisseria gonorrhoeae,&#xD;
                Trichomonas vaginalis, syphilis, human papillomavirus, genital warts and HSV) among&#xD;
                males and females, and cervical HPV-associated pre-cancers and cancers and&#xD;
                Mycoplasma genitalium and other vaginal microbiota among females.&#xD;
&#xD;
             -  Reproductive health, fertility, and pregnancy outcomes including mother-to-child&#xD;
                transmission of HIV.&#xD;
&#xD;
        -  To define the impact of perinatal HIV infection and ART on long-term neurocognitive and&#xD;
           behavioral health outcomes, including:&#xD;
&#xD;
             -  Mental health and neurocognitive functioning.&#xD;
&#xD;
             -  Health care behaviors, including adherence to ART, participation in health care&#xD;
                services, and transition to adult clinical care.&#xD;
&#xD;
             -  Risk behaviors, including sexual behavior and substance use.&#xD;
&#xD;
             -  Independent living skills, and vocational and education achievement necessary for&#xD;
                successful transition to adult functioning and quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HIV disease progression</measure>
    <time_frame>Annually for 6 years</time_frame>
    <description>Factors of interest for this outcome include virologic suppression, immune impairment, immune activation, changes in ART, cumulative exposure to specific ART, viral resistance, co-infections, and host genetic polymorphisms. Data will be collected through chart abstraction and laboratory assessments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolic abnormalities</measure>
    <time_frame>Annually for 6 years</time_frame>
    <description>Factors of interest include BMI, body composition, systolic and diastolic blood pressure, lipid levels (total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides). Data will be collected by chart review, physical assessments, and laboratory evaluations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexually transmitted infections</measure>
    <time_frame>Annually for 6 years</time_frame>
    <description>STI testing and chart review conducted annually.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pregnancies</measure>
    <time_frame>Annually for 6 years</time_frame>
    <description>Data collected annually through online surveys and chart abstraction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mental health problems</measure>
    <time_frame>Every 3 years for 6 years</time_frame>
    <description>Assessed at Entry, Year 3, and Year 6 visits through the NIH Toolbox and Center for Epidemiologic Studies Depression Scale (CES-D).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ART adherence</measure>
    <time_frame>Annually for 6 years</time_frame>
    <description>Data collected annually through an online survey.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of risk behaviors including risky sexual behavior and licit and illicit substance use</measure>
    <time_frame>Annually for 6 years</time_frame>
    <description>Participants will complete an annual online survey.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transition to adult functioning</measure>
    <time_frame>Annually for 6 years</time_frame>
    <description>Every year participants will complete an online survey to collect data on educational attainment, employment, independent living and quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hearing dysfunction</measure>
    <time_frame>Every 3 years for 6 years</time_frame>
    <description>Assessed through the NIH Toolbox and a questionnaire to be completed at Entry, Year 3 and Year 6 visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Language development</measure>
    <time_frame>Once, at the Entry or Year 3 visit</time_frame>
    <description>The Clinical Evaluation of Language Fundamentals (CELF) IV assessment will be completed at the Entry or Year 3 visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>End-organ disease</measure>
    <time_frame>Annually for 6 years</time_frame>
    <description>Factors of interest for this outcome include virologic suppression, immune impairment, immune activation, changes in ART, cumulative exposure to specific ART, viral resistance, co-infections, and host genetic polymorphisms. Data will be collected through chart abstraction and laboratory assessments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Annually for 6 years</time_frame>
    <description>Factors of interest for this outcome include virologic suppression, immune impairment, immune activation, changes in ART, cumulative exposure to specific ART, viral resistance, co-infections, and host genetic polymorphisms. Data will be collected through chart abstraction and laboratory assessments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk factors for cardiovascular disease</measure>
    <time_frame>Annually for 6 years</time_frame>
    <description>Factors of interest include BMI, body composition, systolic and diastolic blood pressure, lipid levels (total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides) and cumulative cardiometabolic risk. Data will be collected by chart review, physical assessments, and laboratory evaluations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cervical HPV-associated pre-cancers and cancers (among female participants)</measure>
    <time_frame>Annually for 6 years</time_frame>
    <description>Data collected through annual chart review.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive impairment</measure>
    <time_frame>Every 3 years for 6 years</time_frame>
    <description>Assessed at Entry, Year 3, and Year 6 visits through the NIH Toolbox.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maternal-to-child HIV transmission</measure>
    <time_frame>Annually for 6 years</time_frame>
    <description>Data collected through annual chart review.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">850</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Infected Cohort</arm_group_label>
    <description>Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment, engaged in care with ART treatment history available.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uninfected Cohort</arm_group_label>
    <description>Perinatally HIV-exposed, perinatally-uninfected participant at or beyond their 18th birthday at enrollment. Must have been previously or currently enrolled in PHACS AMP or PHACS SMARTT, and may have horizontally-acquired HIV infection.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum, peripheral blood monocuclear cells (PBMCs), urine, throat wash/gargle, saliva,&#xD;
      and vaginal swabs.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected and -uninfected young adults 18 years of age or older at the time of&#xD;
        enrollment born to HIV-infected mothers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Perinatally HIV-Infected Cohort&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Perinatal HIV infection as documented in the medical record&#xD;
&#xD;
          -  At or beyond their 18th birthday at the time of informed consent with no upper age&#xD;
             limit&#xD;
&#xD;
          -  Engaged in medical care and medical records are available&#xD;
&#xD;
          -  At least one of the following is true:&#xD;
&#xD;
               -  Previously or currently enrolled in PHACS AMP, or&#xD;
&#xD;
               -  Previously enrolled in any of the studies included on the list of approved&#xD;
                  studies for enrollment into AMP Up, or&#xD;
&#xD;
               -  Available medical record documentation since early childhood of:&#xD;
&#xD;
                    -  ART exposure history&#xD;
&#xD;
                    -  Opportunistic infection prophylaxis exposure history&#xD;
&#xD;
                    -  Viral load and CD4+ cell count history&#xD;
&#xD;
                    -  Major medical events history&#xD;
&#xD;
          -  Willingness to participate and provide legal written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV acquired by other than maternal-child transmission (e.g., blood products, sexual&#xD;
             contact, and IV drug use) as documented in the medical record&#xD;
&#xD;
        Perinatally HIV-Exposed, -Uninfected Cohort&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Perinatally HIV-exposed, perinatally-uninfected as indicated in the medical record;&#xD;
             the PHEU participant may have horizontally-acquired HIV infection&#xD;
&#xD;
          -  At or beyond their 18th birthday at the time of informed consent with no upper age&#xD;
             limit&#xD;
&#xD;
          -  At least one of the following is true:&#xD;
&#xD;
               -  Previously or currently enrolled in PHACS AMP, or&#xD;
&#xD;
               -  Previously or currently enrolled in PHACS SMARTT&#xD;
&#xD;
          -  Willingness to participate and provide legal written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have confirmed perinatal HIV infection as documented in the medical record&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paige L Williams</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health (HSPH)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russell Van Dyke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liz Salomon, EdM</last_name>
    <phone>617-432-6762</phone>
    <email>lsalomon@hsph.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Spector, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elizabeth McFarland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Diagnostic and Treatment Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana Puga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gwendolyn Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ram Yogev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Margarita Silio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Russel Van Dyke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sandra Burchett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers - New Jersey Medical School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arry Dieudonne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronx Lebanon Hospital Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Murli Purswani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Wiznia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Janet Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katherine Knapp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Shearer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Juan Research Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Midnela Acevedo Flores, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.phacsstudy.org</url>
    <description>Pediatric HIV/AIDS Cohort Study</description>
  </link>
  <reference>
    <citation>Torre P 3rd, Russell JS, Smith R, Hoffman HJ, Lee S, Williams PL, Yao TJ; Pediatric HIV/AIDS Cohort Study (PHACS). Words-in-Noise Test Performance in Young Adults Perinatally HIV Infected and Exposed, Uninfected. Am J Audiol. 2020 Mar 5;29(1):68-78. doi: 10.1044/2019_AJA-19-00042. Epub 2020 Jan 31.</citation>
    <PMID>32004075</PMID>
  </reference>
  <reference>
    <citation>Patel K, Karalius B, Powis K, Kacanek D, Berman C, Moscicki AB, Paul M, Tassiopoulos K, Seage GR 3rd; HIV/AIDS Cohort Study (PHACS). Trends in post-partum viral load among women living with perinatal HIV infection in the USA: a prospective cohort study. Lancet HIV. 2020 Mar;7(3):e184-e192. doi: 10.1016/S2352-3018(19)30339-X. Epub 2019 Dec 20.</citation>
    <PMID>31870676</PMID>
  </reference>
  <reference>
    <citation>Tassiopoulos K, Huo Y, Patel K, Kacanek D, Allison S, Siminski S, Nichols SL, Mellins CA; Pediatric HIV/AIDS Cohort Study (PHACS). Healthcare Transition Outcomes Among Young Adults With Perinatally Acquired Human Immunodeficiency Virus Infection in the United States. Clin Infect Dis. 2020 Jun 24;71(1):133-141. doi: 10.1093/cid/ciz747.</citation>
    <PMID>31584617</PMID>
  </reference>
  <reference>
    <citation>Berman CA, Kacanek D, Nichamin M, Wilson D, Davtyan M, Salomon L, Patel K, Reznick M, Tassiopoulos K, Lee S, Bauermeister J, Paul M, Aldape T, Seage Iii GR. Using Social Media and Technology to Communicate in Pediatric HIV Research: Qualitative Study With Young Adults Living With or Exposed to Perinatal HIV. JMIR Pediatr Parent. 2020 Jun 23;3(1):e20712. doi: 10.2196/20712.</citation>
    <PMID>32540839</PMID>
  </reference>
  <results_reference>
    <citation>Tassiopoulos K, Patel K, Alperen J, Kacanek D, Ellis A, Berman C, Allison SM, Hazra R, Barr E, Cantos K, Siminski S, Massagli M, Bauermeister J, Siddiqui DQ, Puga A, Van Dyke R, Seage GR 3rd; Pediatric HIV/AIDS Cohort Study. Following young people with perinatal HIV infection from adolescence into adulthood: the protocol for PHACS AMP Up, a prospective cohort study. BMJ Open. 2016 Jun 9;6(6):e011396. doi: 10.1136/bmjopen-2016-011396.</citation>
    <PMID>27288383</PMID>
  </results_reference>
  <results_reference>
    <citation>Williams PL, Jesson J. Growth and pubertal development in HIV-infected adolescents. Curr Opin HIV AIDS. 2018 May;13(3):179-186. doi: 10.1097/COH.0000000000000450. Review.</citation>
    <PMID>29432228</PMID>
  </results_reference>
  <results_reference>
    <citation>Innes S, Patel K. Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings. Curr Opin HIV AIDS. 2018 May;13(3):187-195. doi: 10.1097/COH.0000000000000458. Review.</citation>
    <PMID>29432231</PMID>
  </results_reference>
  <results_reference>
    <citation>Goodenough CJ, Patel K, Van Dyke RB; Pediatric HIV/AIDS Cohort Study (PHACS). Is There a Higher Risk of Mother-to-child Transmission of HIV Among Pregnant Women With Perinatal HIV Infection? Pediatr Infect Dis J. 2018 Dec;37(12):1267-1270. doi: 10.1097/INF.0000000000002084.</citation>
    <PMID>29742647</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilkinson JD, Williams PL, Yu W, Colan SD, Mendez A, Zachariah JPV, Van Dyke RB, Shearer WT, Margossian RE, Lipshultz SE; Pediatric HIV/AIDS Cohort Study (PHACS). Cardiac and inflammatory biomarkers in perinatally HIV-infected and HIV-exposed uninfected children. AIDS. 2018 Jun 19;32(10):1267-1277. doi: 10.1097/QAD.0000000000001810.</citation>
    <PMID>29596110</PMID>
  </results_reference>
  <results_reference>
    <citation>Alperen J, Davidson J, Siminski S, Seage GR 3rd; Pediatric HIV/AIDS Cohort Study. Utility of the National Death Index in Identifying Deaths in a Clinic-Based, Multisite Cohort: The Experience of the Pediatric HIV/AIDS Cohort Study. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):e37-e39. doi: 10.1097/QAI.0000000000001763.</citation>
    <PMID>29847477</PMID>
  </results_reference>
  <results_reference>
    <citation>Kacanek D, Huo Y, Malee K, Mellins CA, Smith R, Garvie PA, Tassiopoulos K, Lee S, Berman CA, Paul M, Puga A, Allison S; Pediatric HIV/AIDS Cohort Study. Nonadherence and unsuppressed viral load across adolescence among US youth with perinatally acquired HIV. AIDS. 2019 Oct 1;33(12):1923-1934. doi: 10.1097/QAD.0000000000002301.</citation>
    <PMID>31274538</PMID>
  </results_reference>
  <results_reference>
    <citation>Moscicki AB, Karalius B, Tassiopoulos K, Yao TJ, Jacobson DL, Patel K, Purswani M, Seage GR; Pediatric HIV/AIDS Cohort Study. Human Papillomavirus Antibody Levels and Quadrivalent Vaccine Clinical Effectiveness in Perinatally Human Immunodeficiency Virus-infected and Exposed, Uninfected Youth. Clin Infect Dis. 2019 Sep 13;69(7):1183-1191. doi: 10.1093/cid/ciy1040.</citation>
    <PMID>30927547</PMID>
  </results_reference>
  <results_reference>
    <citation>Yildirim C, Garvie PA, Chernoff M, Wilkins ML, Patton ED, Williams PL, Nichols SL; Memory and Executive Functioning Study of the Pediatric HIV/AIDS Cohort Study. The Role of Pharmacy Refill Measures in Assessing Adherence and Predicting HIV Disease Markers in Youth with Perinatally-Acquired HIV (PHIV). AIDS Behav. 2019 Aug;23(8):2109-2120. doi: 10.1007/s10461-019-02468-x.</citation>
    <PMID>30929147</PMID>
  </results_reference>
  <results_reference>
    <citation>Patel K, Seage GR 3rd, Burchett SK, Hazra R, Van Dyke RB; Pediatric HIV/AIDS Cohort Study. Disparities in HIV Viral Suppression Among Adolescents and Young Adults by Perinatal Infection. Am J Public Health. 2019 Jul;109(7):e9. doi: 10.2105/AJPH.2019.305108.</citation>
    <PMID>31166735</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith R, Huo Y, Tassiopoulos K, Rutstein R, Kapetanovic S, Mellins C, Kacanek D, Malee K; Pediatric HIV/AIDS Cohort Study (PHACS). Mental Health Diagnoses, Symptoms, and Service Utilization in US Youth with Perinatal HIV Infection or HIV Exposure. AIDS Patient Care STDS. 2019 Jan;33(1):1-13. doi: 10.1089/apc.2018.0096.</citation>
    <PMID>30601062</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2014</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harvard School of Public Health (HSPH)</investigator_affiliation>
    <investigator_full_name>Paige Williams</investigator_full_name>
    <investigator_title>Senior Lecturer on Biostatistics</investigator_title>
  </responsible_party>
  <keyword>HIV/AIDS, perinatal HIV infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

